AGIL Analysis of Biotech Companies

Essay by anna181University, Master'sA+, May 2006

download word file, 6 pages 5.0 1 reviews

Downloaded 100 times

Centocor Inc, A Johnson & Johnson Company- Centocor utilizes cutting-edge knowledge in biotechnology to discover and develop innovative large and small molecule medicines. Centocor has a leadership position in monoclonal antibody technology. The company creates, acquires and markets unique biopharmaceutical therapies to aid patients in need. Centocor's innovative products focus on the management of three major disease areas; cardiovascular, immunologic disorders and cancer.

AGIL Analysis - Centocor


More emphasis on Direct Sales and Marketing

Low Cost Production

Targeted Markets and Products

Harmonization of processes and systems across all sites and R&D/Manufacturing

Take advantage of the Johnson and Johnson umbrella to achieve goals

Latent Values

Employees (Johnson & Johnson Credo)

Relationships with Customers/End Users (Doctors/Nurses) - (Johnson & Johnson Credo)

Compliance/Regulatory Profile with FDA and International Regulatory Agencies

Delivering Value to Customers

Goal Attainment

$4 Billion in Sales

Penetration; Gain Market Share

Customer Awareness

Cost Differentiation


Maintain capacity to meet anticipated demand for Rheumatoid Arthritis product, Remicade

Low Cost Strategy

Competitive Marketplace

Competitor Reactions

Capacity for Anticipated Demands

2. Amgen

Amgen has been successful in the first round of legal wrangling over a successfully keeping Transkaryotic Therapies (TKT) and its partner, Franco-German drug giant Aventis from marketing a drug similar to the highly profitable Epogen. Amgen's competition that includes Genentech, Chiron, Celera Genomics, Human Genome Sciences, Inc is not intense enough to reduce the amount of profits it takes in. The competition is still a factor but not as much. Amgen is a niche in the non-medically "necessary", but physiologically important medications, including endometriosis. The patients will gladly pay out of pocket for relief. Also, the fear of osteoporosis is enough for the population to pay high costs for any medication proven likely to forestall its consequences. Amgen's competitive strategy includes licensing agreements with competitors, including Johnson & Johnson,